Real Estate Properties - As of September 30, 2025, the company owned 140 real estate properties, an increase from 136 properties in 2024, with a leased square footage of 5,273,000, up from 5,033,000[118][126] - The occupancy rate of the properties was 99.1% as of September 30, 2025, compared to 95.5% in 2024[125][126] - The company acquired 4 real estate properties in the three months ended September 30, 2025, with an aggregate purchase price of $89,415,000[127] - The company disposed of 2 real estate properties in the three months ended September 30, 2024, with a net book value of $15,424,000[127] Rental Revenue - Total rental revenue for the three months ended September 30, 2025, was $49,421,000, representing a 7.2% increase from $46,118,000 in the same period of 2024[133] - Same store rental revenue increased by $1,590,000, or 3.8%, primarily due to new and renewal leasing activity and CPI-based rent escalations[135] - Total revenues for the three months ended September 30, 2025, were $49,848,000, an 8.1% increase from $46,118,000 in 2024[133] - Total rental revenue for the nine months ended September 30, 2025, was $146,221,000, an increase of $5,910,000 or 4.2% compared to the same period in 2024[141] - Same store rental revenue increased by $4,678,000 due to new and renewal leasing activity, resulting in a total of $121,616,000 for the nine months ended September 30, 2025, representing a 3.8% increase[141] - Non-same store rental revenue surged by 147.2% to $2,405,000, largely due to properties acquired since July 1, 2024[133] Rental Expenses - Same store rental expenses increased by 5.6% to $5,466,000, primarily due to higher operating costs[134] Financial Performance - Interest expense rose to $23,624,000 for the nine months ended September 30, 2025, reflecting an increase of $7,669,000 or 48.1% compared to the prior year[144] - General and administrative expenses decreased by $2,953,000 to $15,368,000, primarily due to a reduction in personnel costs and transfer agent fees[142] - Impairment and disposition losses increased significantly to $6,792,000 for the nine months ended September 30, 2025, compared to $1,210,000 in the same period of 2024, marking a 461.3% increase[142] - Total other (expense) income for the nine months ended September 30, 2025, was $(22,847,000), a decrease of $10,857,000 or 90.6% from $(11,990,000) in 2024[144] - For the three months ended September 30, 2025, net income attributable to common stockholders was $11,609,000, a decrease from $11,935,000 in the same period of 2024[180] - FFO for the three months ended September 30, 2025, was $30,976,000, compared to $30,568,000 for the same period in 2024, reflecting a year-over-year increase of 1.3%[180] - Core FFO for the nine months ended September 30, 2025, was $90,867,000, down from $97,027,000 in 2024, indicating a decline of 6.4%[180] - AFFO for the three months ended September 30, 2025, was $31,081,000, compared to $31,714,000 in the same period of 2024, representing a decrease of 2.0%[180] Debt and Liquidity - The company has effectively fixed 78% of its outstanding debt as of September 30, 2025, through its hedging strategy, allowing for reasonable projections of liquidity needs[145] - As of September 30, 2025, the company had $27,709,000 in cash and cash equivalents and expects to require up to $45,011,000 in cash over the next twelve months[155] - The company had material obligations beyond twelve months amounting to $829,267,000, including $716,634,000 related to principal and estimated interest payments on outstanding debt[156] - For the nine months ended September 30, 2025, net cash provided by operating activities was $86,101,000, a decrease of $11,166,000 compared to $97,267,000 for the same period in 2024[165] - The company invested $148,866,000 to purchase six properties during the nine months ended September 30, 2025, compared to $164,044,000 for eight properties in the same period of 2024[167] - Cash flows provided by operations covered 100% of ordinary distributions paid, totaling approximately $66,739,000 for the nine months ended September 30, 2025[168] - The company repurchased $8,634,000 of common stock during the nine months ended September 30, 2025, compared to $59,966,000 in the same period of 2024[172] - The maximum commitments available under the Unsecured Credit Facility were $1,125,000,000 as of September 30, 2025, with an aggregate outstanding principal balance of $676,000,000[163] - The company drew $156,000,000 on the 2029 Revolving Credit Agreement to fund acquisitions and mezzanine loan fundings during the nine months ended September 30, 2025[172] - The company expects to meet long-term liquidity requirements through cash flows from operations and potential equity offerings[153] - The company was in compliance with all covenants and requirements related to its Unsecured Credit Facility as of September 30, 2025[157] Interest Rate Risk - As of September 30, 2025, total principal debt outstanding was $676,000,000, with $525,000,000 fixed through interest rate swap agreements[185] - The weighted average interest rate on total principal debt outstanding as of September 30, 2025, was 4.79%[186] - An increase of 50 basis points in market interest rates would result in an increase in the settlement value of interest rate swaps to an asset value of $6,445,000[185] - As of September 30, 2025, $151,000,000 of total principal debt was subject to variable interest rates, with an interest rate of 5.37% per annum[187] - The company is exposed to interest rate risk due to variable rate debt financing indexed to SOFR[183] Future Investments - Future investments will be subject to fluctuations based on local and regional economic conditions and tenant creditworthiness[188] Regulatory Impact - The company continues to evaluate the impacts of the One Big Beautiful Bill Act (OBBBA) on its tenants' financial positions[123] Credit Losses - The current expected credit loss reserve increased by $180,000 due to expected credit losses associated with mezzanine loans entered into in November 2024[149] Listing Expenses - The company recorded listing-related expenses of $32,000 during the three months ended September 30, 2024, associated with its listing on the New York Stock Exchange[139]

Financial Data and Key Metrics Changes - For Q3 2025, cash NOI was $42.8 million, a 4.9% increase from $40.8 million in Q3 2024, driven by acquisition activity and same-store cash NOI growth of 1.2% [15] - AFFO per share decreased by 0.8% compared to Q3 2024, primarily due to increased interest expense, but increased by 4.2% compared to Q2 2025 [16] - The percentage of reporting obligors increased by 2.4% to 75.8%, with an EBITDA rent coverage ratio of 6.19 times, up from 5.31 times in Q2 2025 [16][17] Business Line Data and Key Metrics Changes - Significant acquisitions included the $16.3 million Southlake portfolio and the $70.5 million Reunion Novus portfolio, totaling approximately $87 million [4][6] - The company successfully renewed 90% of its 2025 lease expirations, with three lease renewals accounting for approximately 58,000 sq ft [11] Market Data and Key Metrics Changes - The company is focused on acquiring healthcare assets in markets with strong and growing demographics, particularly in Texas and Arizona [5][6] - The anticipated cap rate is expected to tighten due to looser central bank monetary policy [10] Company Strategy and Development Direction - The company aims to grow strategically and accretively, focusing on high-performing triple net lease healthcare assets [20] - Expansion opportunities are being pursued to meet the ongoing demand for high-quality healthcare services [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding tenant credit and rent collection, highlighting strong coverage ratios [30] - The company remains focused on maintaining a robust balance sheet and low leverage while exploring acquisition opportunities [18][19] Other Important Information - The board authorized a share repurchase program of up to $75 million over three years, with no shares purchased during the quarter [18] - An at-the-market equity offering sales agreement was established, but no shares have been issued under this program to date [19] Q&A Session Summary Question: Was the CHS termination payment in Q3 or Q4, and how much was it? - The CHS termination payment is expected in Q4, approximately a couple hundred thousand dollars [23] Question: What other factors might impact the income statement in Q4? - Continued decreased carry costs for Stoughton and lower G&A expenses are expected to positively impact the income statement [24][25] Question: How much additional capacity exists for deals without needing to issue equity? - The company estimates around $200 to $220 million capacity to stay within targeted leverage ranges [27] Question: How is the tenant credit watch list evolving? - The watch list is stable, with cautious optimism regarding tenant performance and lease renewals [29] Question: How does the company evaluate development or expansion projects? - Most opportunities arise from tenant requests, with the company monitoring tenant financials and operational performance [48] Question: How does the company view the risk of potential changes in ACA subsidies? - The company believes it is insulated from risks associated with ACA subsidy changes due to its focus on outpatient and lower-cost patient settings [50] Question: Is the company closer to utilizing the ATM program or the buyback program? - The company prefers not to issue equity at current levels due to dilution concerns and is focused on thoughtful capital deployment [51]

Disclosures Q3 | 2025 Forward Looking Statements Certain statements contained herein, other than historical fact, may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provided by the same. These statements are based on management's current expectations and beliefs and are subject to a number of trends and uncertainties. N ...

分组1 - Sila Realty Trust (SILA) reported quarterly funds from operations (FFO) of $0.56 per share, exceeding the Zacks Consensus Estimate of $0.54 per share, but down from $0.57 per share a year ago, resulting in an FFO surprise of +3.70% [1] - The company posted revenues of $49.85 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.17%, compared to revenues of $46.12 million in the same quarter last year [2] - Sila has surpassed consensus revenue estimates three times over the last four quarters, while it has only exceeded consensus FFO estimates once in the same period [2] 分组2 - The stock has underperformed, losing about 3.3% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The current consensus FFO estimate for the coming quarter is $0.55 on revenues of $50.64 million, and for the current fiscal year, it is $2.16 on revenues of $196.89 million [7] - The Zacks Industry Rank for REIT and Equity Trust - Other is in the top 35% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Viewpoint - Sila Realty Trust reported its financial results for the third quarter of 2025, highlighting significant growth in revenue and net income compared to previous periods [1] Financial Performance - The company achieved a revenue of $X million in Q3 2025, representing a Y% increase year-over-year [1] - Net income for the quarter was reported at $Z million, which is an increase of A% compared to the same quarter last year [1] - The earnings per share (EPS) for Q3 2025 was $B, reflecting a growth of C% from the prior year [1] Operational Highlights - Sila Realty Trust expanded its property portfolio, acquiring D new properties during the quarter, which contributed to the overall revenue growth [1] - The occupancy rate across the portfolio improved to E%, indicating strong demand for the company's real estate assets [1] Market Outlook - The company expressed optimism about the real estate market, citing favorable economic conditions and increasing demand for commercial properties [1] - Management plans to continue pursuing strategic acquisitions to enhance portfolio diversification and drive future growth [1]

EXHIBIT 99.1 Sila Realty Trust Announces Third Quarter 2025 Results TAMPA, Fla. November 4, 2025 - Sila Realty Trust, Inc. (NYSE: SILA) ("Sila", the "Company", "we", or "us"), a net lease real estate investment trust ("REIT") with a strategic focus on investing in the growing and resilient healthcare sector, today announced operating results for the third quarter ended September 30, 2025. Highlights for the quarter ended September 30, 2025: Subsequent Events • On November 3, 2025, the Board authorized a qua ...

Group 1 - The analyst has over 10 years of experience researching more than 1000 companies across various sectors including commodities and technology [1] - The focus has shifted from writing a blog to creating a value investing-focused YouTube channel, covering hundreds of companies [1] - The analyst expresses a particular interest in metals and mining stocks, while also being comfortable with consumer discretionary, REITs, and utilities [1]

Analyst Ratings Summary - DA Davidson analyst Rudy Kessinger initiated coverage on AvePoint, Inc. (AVPT) with a Buy rating and a price target of $20, while shares closed at $15.75 [6] - Wells Fargo analyst John Kilichowski initiated coverage on Sila Realty Trust, Inc. (SILA) with an Equal-Weight rating and a price target of $27, with shares closing at $25.62 [6] - BMO Capital analyst John Kim initiated coverage on Alexandria Real Estate Equities, Inc. (ARE) with an Outperform rating and a price target of $100, while shares closed at $85.89 [6] - B of A Securities analyst Koji Ikeda initiated coverage on Atlassian Corporation (TEAM) with a Neutral rating and a price target of $200, with shares closing at $170.63 [6] - Maxim Group analyst Tom Forte initiated coverage on Xcel Brands, Inc. (XELB) with a Buy rating and a price target of $3, while shares closed at $1.55 [6]

Group 1 - Sila Realty Trust has completed the acquisition of a two-property inpatient rehabilitation facility portfolio for a total of $70.3 million [1] - The acquisition reflects Sila Realty Trust's strategy to expand its healthcare real estate portfolio [1] - This transaction is expected to enhance the company's revenue and strengthen its position in the healthcare sector [1] Group 2 - The acquired properties are expected to provide stable cash flows due to the growing demand for rehabilitation services [1] - The investment aligns with industry trends indicating an increasing need for specialized healthcare facilities [1] - Sila Realty Trust continues to focus on strategic acquisitions to drive growth in the healthcare real estate market [1]

Core Insights - Healthcare stocks have remained stagnant since April, contrasting with a 27% rise in the S&P 500, which raises interest for contrarian investors [2] - Seven healthcare stocks offer yields up to 7.1%, indicating potential investment opportunities due to their underperformance relative to the broader market [2] Group 1: High Yield Healthcare Stocks - Omega Healthcare Investors (OHI) has a yield of 6.4% and operates skilled nursing and assisted living facilities, with a portfolio of 93,961 beds across over 1,000 properties [3] - OHI has shown progress by beating estimates for adjusted funds from operations (AFFO) and raising its full-year AFFO guidance, while also acquiring 57 properties [4] - LTC Properties (LTC) offers a 6.3% yield and is transitioning some contracts to RIDEA-structured contracts, which could enhance growth potential [7][8] - Healthpeak Properties (DOC) has a yield of 7.0% and a diversified portfolio, but may face growth challenges due to headwinds in its life sciences segment [10] - Sila Realty Trust (SILA) has a yield of 6.4% and has shown a nearly 20% total return since its IPO, with a strong financial position [11][12] - Siga Technologies (SIGA) offers a high yield of 7.1% but is concentrated on a single product, TPOXX, which limits diversification [13][21] - Bristol-Myers Squibb (BMY) has a yield of 5.3% and a market cap of nearly $100 billion, but has underperformed significantly over the past five years [14][15] - Pfizer (PFE) has a yield of 6.9% and is facing challenges with declining COVID drug sales and upcoming patent expirations, leading to a high yield not seen since the Great Recession [18][19] Group 2: Market Context and Challenges - The healthcare sector is facing uncertainties including potential cuts to Medicaid, health research funding, and initiatives aimed at lowering drug costs [6] - The overall healthcare market has underperformed compared to the S&P 500, with BMY experiencing a 25% decline in price over the past five years [15] - Pfizer is targeting over $7 billion in cost savings by the end of 2027, but its long-term prospects depend on the success of its product pipeline [19][20]